Some observational studies showed that individuals with cardiometabolic disorders (e.g., obesity, MS, and T2D) have higher circulating levels of myonectin compared to controls, and that myonectin is positively correlated with indicators such as BMI, IR, fat mass, and total cholesterol. This evidence concerns the gene ERFE and myeloid sarcoma.